VORICONAZOL SANDOZ 200 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

voriconazol sandoz 200 mg

lek pharmaceuticals d.d. - slovenia - voriconazolum - pulb. pt. sol. perf. - 200 mg - antimicotice de uz sistemic derivati de triazol

VORICONAZOL FRESENIUS KABI 200 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

voriconazol fresenius kabi 200 mg

fresenius kabi deutschland gmbh - germania - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol

MEROPENEM ACCORD 1 g Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

meropenem accord 1 g

accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 1g - alte antibiotice betalactamice carbapeneme

MEROPENEM ACCORD 500 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

meropenem accord 500 mg

accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme

MEROPENEM ACCORD 1 g Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

meropenem accord 1 g

accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 1g - alte antibiotice betalactamice carbapeneme

MEROPENEM ACCORD 500 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

meropenem accord 500 mg

accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme

CASPOFUNGINA MYLAN 70 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

caspofungina mylan 70 mg

sag manufacturing s.l.u - spania - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

PEMETREXED MYLAN 25 mg/ml Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pemetrexed mylan 25 mg/ml

synthon hispania, s.l. - spania - pemetrexedum - conc. pt. sol. perf. - 25mg/ml - antimetaboliti analogi ai acidului folic

VORICONAZOL ACTAVIS 200 mg Romania - Kiromania - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

voriconazol actavis 200 mg

actavis italy s.p.a nerviano plant - italia - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol

Dupixent Umoja wa Ulaya - Kiromania - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.